APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vasodilators for Heart Disease

Compare research editions
View pricing & licenses

Selected research

Industry Research

Vasodilators for Heart Disease Industry Research Report 2026

Report ID 173885130527 December 2025149 pages

Choose your research edition.

Industry ResearchVasodilators for Heart Disease Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Vasodilators for Heart Disease Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Vasodilators for Heart Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vasodilators for Heart Disease Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Vasodilators for Heart Disease Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Vasodilators for Heart Disease market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Vasodilators for Heart Disease is forecast to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Vasodilators for Heart Disease is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Vasodilators for Heart Disease is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Vasodilators for Heart Disease include , among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Vasodilators for Heart Disease market in revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of types and applications, harmonizes vendor attribution, and presents comparable time series by company, type, application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for manufacturers, new entrants, channel partners, and investors; the report also reviews technology shifts and notable product introductions relevant to Vasodilators for Heart Disease.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Vasodilators for Heart Disease Market by Company

Chongqing Yaoyou Pharmaceutical Co., Ltd.

Southwest Pharmaceutical Co., Ltd.

Shanghai Hefeng Pharmaceutical Co., Ltd.

Shanghai Aifa Pharmaceutical Co., Ltd.

Shanxi Kangbao Biological Products Co., Ltd.

Shandong New Era Pharmaceutical Co., Ltd.

Shandong Fangming Pharmaceutical Group Co., Ltd.

Sancai Shiqi Pharmaceutical Co., Ltd.

Lunan Beite Pharmaceutical Co., Ltd.

Jiangxi Haiersi Pharmaceutical Co., Ltd.

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Jiangsu Shenlong Pharmaceutical Co., Ltd.

Jiangsu Jiuxu Pharmaceutical Co., Ltd.

Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd.

Hulunbeier Songlu Pharmaceutical Co., Ltd.

Henan Runhong Pharmaceutical Co., Ltd.

Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.

Chenxin Pharmaceutical Co., Ltd.

Beijing Yimin Pharmaceutical Co., Ltd.

Beijing Hengsheng Pharmaceutical Co., Ltd.

Anhui Fengyuan Pharmaceutical Co., Ltd.

TORRENT PHARMA INC.

Sanofi

Pfizer

Matins Pharma

Copperhead Chemical Company

Axplora

Aditya Chemicals

Vasodilators for Heart Disease Segment by Type

Isosorbide Mononitrate

Nicorandil

Nitroglycerin

Isosorbide Dinitrate

Vasodilators for Heart Disease Segment by Application

Clinic

Hospital

Other

Vasodilators for Heart Disease Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vasodilators for Heart Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vasodilators for Heart Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vasodilators for Heart Disease.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Vasodilators for Heart Disease manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Vasodilators for Heart Disease by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Vasodilators for Heart Disease in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Vasodilators for Heart Disease Production by Manufacturers (Units) & (2021-2026) Table 6. Global Vasodilators for Heart Disease Production Market Share by Manufacturers Table 7. Global Vasodilators for Heart Disease Production Value by Manufacturers (US$ Million) & (2021-2026) Table 8. Global Vasodilators for Heart Disease Production Value Market Share by Manufacturers (2021-2026) Table 9. Global Vasodilators for Heart Disease Average Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Vasodilators for Heart Disease Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Vasodilators for Heart Disease Key Manufacturers, Manufacturing Sites & Headquarters Table 12. Global Vasodilators for Heart Disease Manufacturers, Product Type & Application Table 13. Global Vasodilators for Heart Disease Manufacturers Established Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Vasodilators for Heart Disease by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Production Value of 2025) Table 16. Manufacturers Mergers & Acquisitions, Expansion Plans Table 17. Chongqing Yaoyou Pharmaceutical Co., Ltd. Company Information Table 18. Chongqing Yaoyou Pharmaceutical Co., Ltd. Business Overview Table 19. Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 20. Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 21. Chongqing Yaoyou Pharmaceutical Co., Ltd. Recent Development Table 22. Southwest Pharmaceutical Co., Ltd. Company Information Table 23. Southwest Pharmaceutical Co., Ltd. Business Overview Table 24. Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 25. Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 26. Southwest Pharmaceutical Co., Ltd. Recent Development Table 27. Shanghai Hefeng Pharmaceutical Co., Ltd. Company Information Table 28. Shanghai Hefeng Pharmaceutical Co., Ltd. Business Overview Table 29. Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 30. Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 31. Shanghai Hefeng Pharmaceutical Co., Ltd. Recent Development Table 32. Shanghai Aifa Pharmaceutical Co., Ltd. Company Information Table 33. Shanghai Aifa Pharmaceutical Co., Ltd. Business Overview Table 34. Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 35. Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 36. Shanghai Aifa Pharmaceutical Co., Ltd. Recent Development Table 37. Shanxi Kangbao Biological Products Co., Ltd. Company Information Table 38. Shanxi Kangbao Biological Products Co., Ltd. Business Overview Table 39. Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 40. Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 41. Shanxi Kangbao Biological Products Co., Ltd. Recent Development Table 42. Shandong New Era Pharmaceutical Co., Ltd. Company Information Table 43. Shandong New Era Pharmaceutical Co., Ltd. Business Overview Table 44. Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 46. Shandong New Era Pharmaceutical Co., Ltd. Recent Development Table 47. Shandong Fangming Pharmaceutical Group Co., Ltd. Company Information Table 48. Shandong Fangming Pharmaceutical Group Co., Ltd. Business Overview Table 49. Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 50. Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 51. Shandong Fangming Pharmaceutical Group Co., Ltd. Recent Development Table 52. Sancai Shiqi Pharmaceutical Co., Ltd. Company Information Table 53. Sancai Shiqi Pharmaceutical Co., Ltd. Business Overview Table 54. Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 55. Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 56. Sancai Shiqi Pharmaceutical Co., Ltd. Recent Development Table 57. Lunan Beite Pharmaceutical Co., Ltd. Company Information Table 58. Lunan Beite Pharmaceutical Co., Ltd. Business Overview Table 59. Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 61. Lunan Beite Pharmaceutical Co., Ltd. Recent Development Table 62. Jiangxi Haiersi Pharmaceutical Co., Ltd. Company Information Table 63. Jiangxi Haiersi Pharmaceutical Co., Ltd. Business Overview Table 64. Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 66. Jiangxi Haiersi Pharmaceutical Co., Ltd. Recent Development Table 67. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information Table 68. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview Table 69. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 71. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Development Table 72. Jiangsu Shenlong Pharmaceutical Co., Ltd. Company Information Table 73. Jiangsu Shenlong Pharmaceutical Co., Ltd. Business Overview Table 74. Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 76. Jiangsu Shenlong Pharmaceutical Co., Ltd. Recent Development Table 77. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Company Information Table 78. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Business Overview Table 79. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 81. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Recent Development Table 82. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Company Information Table 83. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Business Overview Table 84. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 86. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Recent Development Table 87. Hulunbeier Songlu Pharmaceutical Co., Ltd. Company Information Table 88. Hulunbeier Songlu Pharmaceutical Co., Ltd. Business Overview Table 89. Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 91. Hulunbeier Songlu Pharmaceutical Co., Ltd. Recent Development Table 92. Henan Runhong Pharmaceutical Co., Ltd. Company Information Table 93. Henan Runhong Pharmaceutical Co., Ltd. Business Overview Table 94. Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 96. Henan Runhong Pharmaceutical Co., Ltd. Recent Development Table 97. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Company Information Table 98. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Business Overview Table 99. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 101. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Recent Development Table 102. Chenxin Pharmaceutical Co., Ltd. Company Information Table 103. Chenxin Pharmaceutical Co., Ltd. Business Overview Table 104. Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 106. Chenxin Pharmaceutical Co., Ltd. Recent Development Table 107. Beijing Yimin Pharmaceutical Co., Ltd. Company Information Table 108. Beijing Yimin Pharmaceutical Co., Ltd. Business Overview Table 109. Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 111. Beijing Yimin Pharmaceutical Co., Ltd. Recent Development Table 112. Beijing Hengsheng Pharmaceutical Co., Ltd. Company Information Table 113. Beijing Hengsheng Pharmaceutical Co., Ltd. Business Overview Table 114. Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 116. Beijing Hengsheng Pharmaceutical Co., Ltd. Recent Development Table 117. Anhui Fengyuan Pharmaceutical Co., Ltd. Company Information Table 118. Anhui Fengyuan Pharmaceutical Co., Ltd. Business Overview Table 119. Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 121. Anhui Fengyuan Pharmaceutical Co., Ltd. Recent Development Table 122. TORRENT PHARMA INC. Company Information Table 123. TORRENT PHARMA INC. Business Overview Table 124. TORRENT PHARMA INC. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. TORRENT PHARMA INC. Vasodilators for Heart Disease Product Portfolio Table 126. TORRENT PHARMA INC. Recent Development Table 127. Sanofi Company Information Table 128. Sanofi Business Overview Table 129. Sanofi Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Sanofi Vasodilators for Heart Disease Product Portfolio Table 131. Sanofi Recent Development Table 132. Pfizer Company Information Table 133. Pfizer Business Overview Table 134. Pfizer Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Pfizer Vasodilators for Heart Disease Product Portfolio Table 136. Pfizer Recent Development Table 137. Matins Pharma Company Information Table 138. Matins Pharma Business Overview Table 139. Matins Pharma Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Matins Pharma Vasodilators for Heart Disease Product Portfolio Table 141. Matins Pharma Recent Development Table 142. Copperhead Chemical Company Company Information Table 143. Copperhead Chemical Company Business Overview Table 144. Copperhead Chemical Company Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Copperhead Chemical Company Vasodilators for Heart Disease Product Portfolio Table 146. Copperhead Chemical Company Recent Development Table 147. Axplora Company Information Table 148. Axplora Business Overview Table 149. Axplora Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Axplora Vasodilators for Heart Disease Product Portfolio Table 151. Axplora Recent Development Table 152. Aditya Chemicals Company Information Table 153. Aditya Chemicals Business Overview Table 154. Aditya Chemicals Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Aditya Chemicals Vasodilators for Heart Disease Product Portfolio Table 156. Aditya Chemicals Recent Development Table 157. Global Vasodilators for Heart Disease Production Comparison by Region: 2021 VS 2025 VS 2032 (Units) Table 158. Global Vasodilators for Heart Disease Production by Region (2021-2026) & (Units) Table 159. Global Vasodilators for Heart Disease Production Market Share by Region (2021-2026) Table 160. Global Vasodilators for Heart Disease Production Forecast by Region (2027-2032) & (Units) Table 161. Global Vasodilators for Heart Disease Production Market Share Forecast by Region (2027-2032) Table 162. Global Vasodilators for Heart Disease Production Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 163. Global Vasodilators for Heart Disease Production Value by Region (2021-2026) & (US$ Million) Table 164. Global Vasodilators for Heart Disease Production Value Market Share by Region (2021-2026) Table 165. Global Vasodilators for Heart Disease Production Value Forecast by Region (2027-2032) & (US$ Million) Table 166. Global Vasodilators for Heart Disease Market Average Price (US$/Unit) by Region (2021-2026) Table 167. Global Vasodilators for Heart Disease Market Average Price (US$/Unit) by Region (2027-2032) Table 168. Global Vasodilators for Heart Disease Consumption Comparison by Region: 2021 VS 2025 VS 2032 (Units) Table 169. Global Vasodilators for Heart Disease Consumption by Region (2021-2026) & (Units) Table 170. Global Vasodilators for Heart Disease Consumption Market Share by Region (2021-2026) Table 171. Global Vasodilators for Heart Disease Forecasted Consumption by Region (2027-2032) & (Units) Table 172. Global Vasodilators for Heart Disease Forecasted Consumption Market Share by Region (2027-2032) Table 173. North America Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 174. North America Vasodilators for Heart Disease Consumption by Country (2021-2026) & (Units) Table 175. North America Vasodilators for Heart Disease Consumption by Country (2027-2032) & (Units) Table 176. Europe Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 177. Europe Vasodilators for Heart Disease Consumption by Country (2021-2026) & (Units) Table 178. Europe Vasodilators for Heart Disease Consumption by Country (2027-2032) & (Units) Table 179. Asia Pacific Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 180. Asia Pacific Vasodilators for Heart Disease Consumption by Country (2021-2026) & (Units) Table 181. Asia Pacific Vasodilators for Heart Disease Consumption by Country (2027-2032) & (Units) Table 182. South America, Middle East & Africa Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 183. South America, Middle East & Africa Vasodilators for Heart Disease Consumption by Country (2021-2026) & (Units) Table 184. South America, Middle East & Africa Vasodilators for Heart Disease Consumption by Country (2027-2032) & (Units) Table 185. Global Vasodilators for Heart Disease Production by Type (2021-2026) & (Units) Table 186. Global Vasodilators for Heart Disease Production by Type (2027-2032) & (Units) Table 187. Global Vasodilators for Heart Disease Production Market Share by Type (2021-2026) Table 188. Global Vasodilators for Heart Disease Production Market Share by Type (2027-2032) Table 189. Global Vasodilators for Heart Disease Production Value by Type (2021-2026) & (US$ Million) Table 190. Global Vasodilators for Heart Disease Production Value by Type (2027-2032) & (US$ Million) Table 191. Global Vasodilators for Heart Disease Production Value Market Share by Type (2021-2026) Table 192. Global Vasodilators for Heart Disease Production Value Market Share by Type (2027-2032) Table 193. Global Vasodilators for Heart Disease Price by Type (2021-2026) & (US$/Unit) Table 194. Global Vasodilators for Heart Disease Price by Type (2027-2032) & (US$/Unit) Table 195. Global Vasodilators for Heart Disease Production by Application (2021-2026) & (Units) Table 196. Global Vasodilators for Heart Disease Production by Application (2027-2032) & (Units) Table 197. Global Vasodilators for Heart Disease Production Market Share by Application (2021-2026) Table 198. Global Vasodilators for Heart Disease Production Market Share by Application (2027-2032) Table 199. Global Vasodilators for Heart Disease Production Value by Application (2021-2026) & (US$ Million) Table 200. Global Vasodilators for Heart Disease Production Value by Application (2027-2032) & (US$ Million) Table 201. Global Vasodilators for Heart Disease Production Value Market Share by Application (2021-2026) Table 202. Global Vasodilators for Heart Disease Production Value Market Share by Application (2027-2032) Table 203. Global Vasodilators for Heart Disease Price by Application (2021-2026) & (US$/Unit) Table 204. Global Vasodilators for Heart Disease Price by Application (2027-2032) & (US$/Unit) Table 205. Key Raw Materials Table 206. Raw Materials Key Suppliers Table 207. Vasodilators for Heart Disease Distributors List Table 208. Vasodilators for Heart Disease Customers List Table 209. Vasodilators for Heart Disease Industry Trends Table 210. Vasodilators for Heart Disease Industry Drivers Table 211. Vasodilators for Heart Disease Industry Restraints Table 212. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Vasodilators for Heart Disease Product Image Figure 5. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Isosorbide Mononitrate Product Image Figure 7. Nicorandil Product Image Figure 8. Nitroglycerin Product Image Figure 9. Isosorbide Dinitrate Product Image Figure 10. Clinic Product Image Figure 11. Hospital Product Image Figure 12. Other Product Image Figure 13. Global Vasodilators for Heart Disease Production Value (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Vasodilators for Heart Disease Production Value (2021-2032) & (US$ Million) Figure 15. Global Vasodilators for Heart Disease Production Capacity (2021-2032) & (Units) Figure 16. Global Vasodilators for Heart Disease Production (2021-2032) & (Units) Figure 17. Global Vasodilators for Heart Disease Average Price (US$/Unit) & (2021-2032) Figure 18. Global Vasodilators for Heart Disease Key Manufacturers, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Vasodilators for Heart Disease Players Market Share by Production Value in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Vasodilators for Heart Disease Production Comparison by Region: 2021 VS 2025 VS 2032 (Units) Figure 22. Global Vasodilators for Heart Disease Production Market Share by Region: 2021 VS 2025 VS 2032 Figure 23. Global Vasodilators for Heart Disease Production Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Vasodilators for Heart Disease Production Value Market Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Vasodilators for Heart Disease Production Value (US$ Million) Growth Rate (2021-2032) Figure 26. Europe Vasodilators for Heart Disease Production Value (US$ Million) Growth Rate (2021-2032) Figure 27. China Vasodilators for Heart Disease Production Value (US$ Million) Growth Rate (2021-2032) Figure 28. Japan Vasodilators for Heart Disease Production Value (US$ Million) Growth Rate (2021-2032) Figure 29. Global Vasodilators for Heart Disease Consumption Comparison by Region: 2021 VS 2025 VS 2032 (Units) Figure 30. Global Vasodilators for Heart Disease Consumption Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 32. North America Vasodilators for Heart Disease Consumption Market Share by Country (2021-2032) Figure 33. United States Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 34. United States Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 35. Canada Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 36. Mexico Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 37. Europe Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 38. Europe Vasodilators for Heart Disease Consumption Market Share by Country (2021-2032) Figure 39. Germany Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 40. France Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 41. U.K. Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 42. Italy Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 43. Russia Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 44. Spain Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 45. Netherlands Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 46. Switzerland Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 47. Sweden Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 48. Poland Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 49. Asia Pacific Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 50. Asia Pacific Vasodilators for Heart Disease Consumption Market Share by Country (2021-2032) Figure 51. China Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 52. Japan Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 53. South Korea Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 54. India Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 55. Australia Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 56. Taiwan Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 57. Southeast Asia Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 58. South America, Middle East & Africa Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 59. South America, Middle East & Africa Vasodilators for Heart Disease Consumption Market Share by Country (2021-2032) Figure 60. Brazil Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 61. Argentina Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 62. Chile Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 63. Turkey Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 64. GCC Countries Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 65. Global Vasodilators for Heart Disease Production Market Share by Type (2021-2032) Figure 66. Global Vasodilators for Heart Disease Production Value Market Share by Type (2021-2032) Figure 67. Global Vasodilators for Heart Disease Price (US$/Unit) by Type (2021-2032) Figure 68. Global Vasodilators for Heart Disease Production Market Share by Application (2021-2032) Figure 69. Global Vasodilators for Heart Disease Production Value Market Share by Application (2021-2032) Figure 70. Global Vasodilators for Heart Disease Price (US$/Unit) by Application (2021-2032) Figure 71. Vasodilators for Heart Disease Value Chain Figure 72. Vasodilators for Heart Disease Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Vasodilators for Heart Disease Industry Opportunities and Challenges

Scope & coverage.

Types
  • Isosorbide Mononitrate
  • Nicorandil
  • Nitroglycerin
  • Isosorbide Dinitrate
Applications
  • Clinic
  • Hospital
  • Other
Companies covered
  • Chongqing Yaoyou Pharmaceutical Co., Ltd.
  • Southwest Pharmaceutical Co., Ltd.
  • Shanghai Hefeng Pharmaceutical Co., Ltd.
  • Shanghai Aifa Pharmaceutical Co., Ltd.
  • Shanxi Kangbao Biological Products Co., Ltd.
  • Shandong New Era Pharmaceutical Co., Ltd.
  • Shandong Fangming Pharmaceutical Group Co., Ltd.
  • Sancai Shiqi Pharmaceutical Co., Ltd.
  • Lunan Beite Pharmaceutical Co., Ltd.
  • Jiangxi Haiersi Pharmaceutical Co., Ltd.
  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  • Jiangsu Shenlong Pharmaceutical Co., Ltd.
  • Jiangsu Jiuxu Pharmaceutical Co., Ltd.
  • Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd.
  • Hulunbeier Songlu Pharmaceutical Co., Ltd.
  • Henan Runhong Pharmaceutical Co., Ltd.
  • Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.
  • Chenxin Pharmaceutical Co., Ltd.
  • Beijing Yimin Pharmaceutical Co., Ltd.
  • Beijing Hengsheng Pharmaceutical Co., Ltd.
  • Anhui Fengyuan Pharmaceutical Co., Ltd.
  • TORRENT PHARMA INC.
  • Sanofi
  • Pfizer
  • Matins Pharma
  • Copperhead Chemical Company
  • Axplora
  • Aditya Chemicals

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Vasodilators for Heart Disease by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  4. 2.2.2 Isosorbide Mononitrate
  5. 2.2.3 Nicorandil
  6. 2.2.4 Nitroglycerin
  7. 2.2.5 Isosorbide Dinitrate
  8. 2.3 Vasodilators for Heart Disease by Application
  9. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
  10. 2.3.2 Clinic
  11. 2.3.3 Hospital
  12. 2.3.4 Other
  13. 2.4 Global Market Growth Prospects
  14. 2.4.1 Global Vasodilators for Heart Disease Production Value Estimates and Forecasts (2021-2032)
  15. 2.4.2 Global Vasodilators for Heart Disease Production Capacity Estimates and Forecasts (2021-2032)
  16. 2.4.3 Global Vasodilators for Heart Disease Production Estimates and Forecasts (2021-2032)
  17. 2.4.4 Global Vasodilators for Heart Disease Market Average Price (2021-2032)
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Vasodilators for Heart Disease Production by Manufacturers (2021-2026)
  2. 3.2 Global Vasodilators for Heart Disease Production Value by Manufacturers (2021-2026)
  3. 3.3 Global Vasodilators for Heart Disease Average Price by Manufacturers (2021-2026)
  4. 3.4 Global Vasodilators for Heart Disease Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vasodilators for Heart Disease Key Manufacturers, Manufacturing Sites & Headquarters
  6. 3.6 Global Vasodilators for Heart Disease Manufacturers, Product Type & Application
  7. 3.7 Global Vasodilators for Heart Disease Manufacturers Established Date
  8. 3.8 Global Vasodilators for Heart Disease Market CR5 and HHI
  9. 3.9 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Chongqing Yaoyou Pharmaceutical Co., Ltd.
  2. 4.1.1 Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  3. 4.1.2 Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  4. 4.1.3 Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  5. 4.1.4 Chongqing Yaoyou Pharmaceutical Co., Ltd. Product Portfolio
  6. 4.1.5 Chongqing Yaoyou Pharmaceutical Co., Ltd. Recent Developments
  7. 4.2 Southwest Pharmaceutical Co., Ltd.
  8. 4.2.1 Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  9. 4.2.2 Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  10. 4.2.3 Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  11. 4.2.4 Southwest Pharmaceutical Co., Ltd. Product Portfolio
  12. 4.2.5 Southwest Pharmaceutical Co., Ltd. Recent Developments
  13. 4.3 Shanghai Hefeng Pharmaceutical Co., Ltd.
  14. 4.3.1 Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  15. 4.3.2 Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  16. 4.3.3 Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  17. 4.3.4 Shanghai Hefeng Pharmaceutical Co., Ltd. Product Portfolio
  18. 4.3.5 Shanghai Hefeng Pharmaceutical Co., Ltd. Recent Developments
  19. 4.4 Shanghai Aifa Pharmaceutical Co., Ltd.
  20. 4.4.1 Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  21. 4.4.2 Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  22. 4.4.3 Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  23. 4.4.4 Shanghai Aifa Pharmaceutical Co., Ltd. Product Portfolio
  24. 4.4.5 Shanghai Aifa Pharmaceutical Co., Ltd. Recent Developments
  25. 4.5 Shanxi Kangbao Biological Products Co., Ltd.
  26. 4.5.1 Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Company Information
  27. 4.5.2 Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Business Overview
  28. 4.5.3 Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  29. 4.5.4 Shanxi Kangbao Biological Products Co., Ltd. Product Portfolio
  30. 4.5.5 Shanxi Kangbao Biological Products Co., Ltd. Recent Developments
  31. 4.6 Shandong New Era Pharmaceutical Co., Ltd.
  32. 4.6.1 Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  33. 4.6.2 Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  34. 4.6.3 Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  35. 4.6.4 Shandong New Era Pharmaceutical Co., Ltd. Product Portfolio
  36. 4.6.5 Shandong New Era Pharmaceutical Co., Ltd. Recent Developments
  37. 4.7 Shandong Fangming Pharmaceutical Group Co., Ltd.
  38. 4.7.1 Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Company Information
  39. 4.7.2 Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Business Overview
  40. 4.7.3 Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  41. 4.7.4 Shandong Fangming Pharmaceutical Group Co., Ltd. Product Portfolio
  42. 4.7.5 Shandong Fangming Pharmaceutical Group Co., Ltd. Recent Developments
  43. 4.8 Sancai Shiqi Pharmaceutical Co., Ltd.
  44. 4.8.1 Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  45. 4.8.2 Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  46. 4.8.3 Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  47. 4.8.4 Sancai Shiqi Pharmaceutical Co., Ltd. Product Portfolio
  48. 4.8.5 Sancai Shiqi Pharmaceutical Co., Ltd. Recent Developments
  49. 4.9 Lunan Beite Pharmaceutical Co., Ltd.
  50. 4.9.1 Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  51. 4.9.2 Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  52. 4.9.3 Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  53. 4.9.4 Lunan Beite Pharmaceutical Co., Ltd. Product Portfolio
  54. 4.9.5 Lunan Beite Pharmaceutical Co., Ltd. Recent Developments
  55. 4.10 Jiangxi Haiersi Pharmaceutical Co., Ltd.
  56. 4.10.1 Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  57. 4.10.2 Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  58. 4.10.3 Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  59. 4.10.4 Jiangxi Haiersi Pharmaceutical Co., Ltd. Product Portfolio
  60. 4.10.5 Jiangxi Haiersi Pharmaceutical Co., Ltd. Recent Developments
  61. 4.11 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  62. 4.11.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  63. 4.11.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  64. 4.11.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  65. 4.11.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Product Portfolio
  66. 4.11.5 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Developments
  67. 4.12 Jiangsu Shenlong Pharmaceutical Co., Ltd.
  68. 4.12.1 Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  69. 4.12.2 Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  70. 4.12.3 Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  71. 4.12.4 Jiangsu Shenlong Pharmaceutical Co., Ltd. Product Portfolio
  72. 4.12.5 Jiangsu Shenlong Pharmaceutical Co., Ltd. Recent Developments
  73. 4.13 Jiangsu Jiuxu Pharmaceutical Co., Ltd.
  74. 4.13.1 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  75. 4.13.2 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  76. 4.13.3 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  77. 4.13.4 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Product Portfolio
  78. 4.13.5 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Recent Developments
  79. 4.14 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd.
  80. 4.14.1 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  81. 4.14.2 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  82. 4.14.3 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  83. 4.14.4 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Product Portfolio
  84. 4.14.5 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Recent Developments
  85. 4.15 Hulunbeier Songlu Pharmaceutical Co., Ltd.
  86. 4.15.1 Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  87. 4.15.2 Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  88. 4.15.3 Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  89. 4.15.4 Hulunbeier Songlu Pharmaceutical Co., Ltd. Product Portfolio
  90. 4.15.5 Hulunbeier Songlu Pharmaceutical Co., Ltd. Recent Developments
  91. 4.16 Henan Runhong Pharmaceutical Co., Ltd.
  92. 4.16.1 Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  93. 4.16.2 Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  94. 4.16.3 Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  95. 4.16.4 Henan Runhong Pharmaceutical Co., Ltd. Product Portfolio
  96. 4.16.5 Henan Runhong Pharmaceutical Co., Ltd. Recent Developments
  97. 4.17 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.
  98. 4.17.1 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  99. 4.17.2 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  100. 4.17.3 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  101. 4.17.4 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Product Portfolio
  102. 4.17.5 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Recent Developments
  103. 4.18 Chenxin Pharmaceutical Co., Ltd.
  104. 4.18.1 Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  105. 4.18.2 Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  106. 4.18.3 Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  107. 4.18.4 Chenxin Pharmaceutical Co., Ltd. Product Portfolio
  108. 4.18.5 Chenxin Pharmaceutical Co., Ltd. Recent Developments
  109. 4.19 Beijing Yimin Pharmaceutical Co., Ltd.
  110. 4.19.1 Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  111. 4.19.2 Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  112. 4.19.3 Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  113. 4.19.4 Beijing Yimin Pharmaceutical Co., Ltd. Product Portfolio
  114. 4.19.5 Beijing Yimin Pharmaceutical Co., Ltd. Recent Developments
  115. 4.20 Beijing Hengsheng Pharmaceutical Co., Ltd.
  116. 4.20.1 Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  117. 4.20.2 Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  118. 4.20.3 Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  119. 4.20.4 Beijing Hengsheng Pharmaceutical Co., Ltd. Product Portfolio
  120. 4.20.5 Beijing Hengsheng Pharmaceutical Co., Ltd. Recent Developments
  121. 4.21 Anhui Fengyuan Pharmaceutical Co., Ltd.
  122. 4.21.1 Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Company Information
  123. 4.21.2 Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Business Overview
  124. 4.21.3 Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  125. 4.21.4 Anhui Fengyuan Pharmaceutical Co., Ltd. Product Portfolio
  126. 4.21.5 Anhui Fengyuan Pharmaceutical Co., Ltd. Recent Developments
  127. 4.22 TORRENT PHARMA INC.
  128. 4.22.1 TORRENT PHARMA INC. Vasodilators for Heart Disease Company Information
  129. 4.22.2 TORRENT PHARMA INC. Vasodilators for Heart Disease Business Overview
  130. 4.22.3 TORRENT PHARMA INC. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  131. 4.22.4 TORRENT PHARMA INC. Product Portfolio
  132. 4.22.5 TORRENT PHARMA INC. Recent Developments
  133. 4.23 Sanofi
  134. 4.23.1 Sanofi Vasodilators for Heart Disease Company Information
  135. 4.23.2 Sanofi Vasodilators for Heart Disease Business Overview
  136. 4.23.3 Sanofi Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  137. 4.23.4 Sanofi Product Portfolio
  138. 4.23.5 Sanofi Recent Developments
  139. 4.24 Pfizer
  140. 4.24.1 Pfizer Vasodilators for Heart Disease Company Information
  141. 4.24.2 Pfizer Vasodilators for Heart Disease Business Overview
  142. 4.24.3 Pfizer Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  143. 4.24.4 Pfizer Product Portfolio
  144. 4.24.5 Pfizer Recent Developments
  145. 4.25 Matins Pharma
  146. 4.25.1 Matins Pharma Vasodilators for Heart Disease Company Information
  147. 4.25.2 Matins Pharma Vasodilators for Heart Disease Business Overview
  148. 4.25.3 Matins Pharma Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  149. 4.25.4 Matins Pharma Product Portfolio
  150. 4.25.5 Matins Pharma Recent Developments
  151. 4.26 Copperhead Chemical Company
  152. 4.26.1 Copperhead Chemical Company Vasodilators for Heart Disease Company Information
  153. 4.26.2 Copperhead Chemical Company Vasodilators for Heart Disease Business Overview
  154. 4.26.3 Copperhead Chemical Company Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  155. 4.26.4 Copperhead Chemical Company Product Portfolio
  156. 4.26.5 Copperhead Chemical Company Recent Developments
  157. 4.27 Axplora
  158. 4.27.1 Axplora Vasodilators for Heart Disease Company Information
  159. 4.27.2 Axplora Vasodilators for Heart Disease Business Overview
  160. 4.27.3 Axplora Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  161. 4.27.4 Axplora Product Portfolio
  162. 4.27.5 Axplora Recent Developments
  163. 4.28 Aditya Chemicals
  164. 4.28.1 Aditya Chemicals Vasodilators for Heart Disease Company Information
  165. 4.28.2 Aditya Chemicals Vasodilators for Heart Disease Business Overview
  166. 4.28.3 Aditya Chemicals Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  167. 4.28.4 Aditya Chemicals Product Portfolio
  168. 4.28.5 Aditya Chemicals Recent Developments
5 Global Vasodilators for Heart Disease Production by Region
  1. 5.1 Global Vasodilators for Heart Disease Production Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Vasodilators for Heart Disease Production by Region: 2021-2032
  3. 5.2.1 Global Vasodilators for Heart Disease Production by Region: 2021-2026
  4. 5.2.2 Global Vasodilators for Heart Disease Production Forecast by Region (2027-2032)
  5. 5.3 Global Vasodilators for Heart Disease Production Value Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
  6. 5.4 Global Vasodilators for Heart Disease Production Value by Region: 2021-2032
  7. 5.4.1 Global Vasodilators for Heart Disease Production Value by Region: 2021-2026
  8. 5.4.2 Global Vasodilators for Heart Disease Production Value Forecast by Region (2027-2032)
  9. 5.5 Global Vasodilators for Heart Disease Market Price Analysis by Region (2021-2026)
  10. 5.6 Global Vasodilators for Heart Disease Production and Value, YOY Growth
  11. 5.6.1 North America Vasodilators for Heart Disease Production Value Estimates and Forecasts (2021-2032)
  12. 5.6.2 Europe Vasodilators for Heart Disease Production Value Estimates and Forecasts (2021-2032)
  13. 5.6.3 China Vasodilators for Heart Disease Production Value Estimates and Forecasts (2021-2032)
  14. 5.6.4 Japan Vasodilators for Heart Disease Production Value Estimates and Forecasts (2021-2032)
6 Global Vasodilators for Heart Disease Consumption by Region
  1. 6.1 Global Vasodilators for Heart Disease Consumption Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vasodilators for Heart Disease Consumption by Region (2021-2032)
  3. 6.2.1 Global Vasodilators for Heart Disease Consumption by Region: 2021-2026
  4. 6.2.2 Global Vasodilators for Heart Disease Forecasted Consumption by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Vasodilators for Heart Disease Consumption by Country (2021-2032)
  8. 6.3.3 United States
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Vasodilators for Heart Disease Consumption by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Russia
  19. 6.4.8 Spain
  20. 6.4.9 Netherlands
  21. 6.4.10 Switzerland
  22. 6.4.11 Sweden
  23. 6.4.12 Poland
  24. 6.5 Asia Pacific
  25. 6.5.1 Asia Pacific Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  26. 6.5.2 Asia Pacific Vasodilators for Heart Disease Consumption by Country (2021-2032)
  27. 6.5.3 China
  28. 6.5.4 Japan
  29. 6.5.5 South Korea
  30. 6.5.6 India
  31. 6.5.7 Australia
  32. 6.5.8 Taiwan
  33. 6.5.9 Southeast Asia
  34. 6.6 South America, Middle East & Africa
  35. 6.6.1 South America, Middle East & Africa Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  36. 6.6.2 South America, Middle East & Africa Vasodilators for Heart Disease Consumption by Country (2021-2032)
  37. 6.6.3 Brazil
  38. 6.6.4 Argentina
  39. 6.6.5 Chile
  40. 6.6.6 Turkey
  41. 6.6.7 GCC Countries
7 Segment by Type
  1. 7.1 Global Vasodilators for Heart Disease Production by Type (2021-2032)
  2. 7.1.1 Global Vasodilators for Heart Disease Production by Type (2021-2032) & (Units)
  3. 7.1.2 Global Vasodilators for Heart Disease Production Market Share by Type (2021-2032)
  4. 7.2 Global Vasodilators for Heart Disease Production Value by Type (2021-2032)
  5. 7.2.1 Global Vasodilators for Heart Disease Production Value by Type (2021-2032) & (US$ Million)
  6. 7.2.2 Global Vasodilators for Heart Disease Production Value Market Share by Type (2021-2032)
  7. 7.3 Global Vasodilators for Heart Disease Price by Type (2021-2032)
8 Segment by Application
  1. 8.1 Global Vasodilators for Heart Disease Production by Application (2021-2032)
  2. 8.1.1 Global Vasodilators for Heart Disease Production by Application (2021-2032) & (Units)
  3. 8.1.2 Global Vasodilators for Heart Disease Production Market Share by Application (2021-2032)
  4. 8.2 Global Vasodilators for Heart Disease Production Value by Application (2021-2032)
  5. 8.2.1 Global Vasodilators for Heart Disease Production Value by Application (2021-2032) & (US$ Million)
  6. 8.2.2 Global Vasodilators for Heart Disease Production Value Market Share by Application (2021-2032)
  7. 8.3 Global Vasodilators for Heart Disease Price by Application (2021-2032)
9 Value Chain and Sales Channels Analysis of the Market
  1. 9.1 Vasodilators for Heart Disease Value Chain Analysis
  2. 9.1.1 Vasodilators for Heart Disease Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Vasodilators for Heart Disease Production Mode & Process
  5. 9.2 Vasodilators for Heart Disease Sales Channels Analysis
  6. 9.2.1 Direct Comparison with Distribution Share
  7. 9.2.2 Vasodilators for Heart Disease Distributors
  8. 9.2.3 Vasodilators for Heart Disease Customers
10 Global Vasodilators for Heart Disease Analyzing Market Dynamics
  1. 10.1 Vasodilators for Heart Disease Industry Trends
  2. 10.2 Vasodilators for Heart Disease Industry Drivers
  3. 10.3 Vasodilators for Heart Disease Industry Opportunities and Challenges
  4. 10.4 Vasodilators for Heart Disease Industry Restraints
11 Report Conclusion
    12 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst